Introduction
In recent years the steps involved in Ras activation by tyrosine kinase receptors have become increasingly clear. The adaptor protein Shc is an early mediator of this process (Rozakis-Adcock et al., 1992) . Shc contains an N-terminal phosphotyrosine binding motif (PTB), a central collagen homology domain (CH) where the primary site of tyrosine phosphorylation (Y317) resides, and a C-terminal SH2 domain (Kavanaugh and Williams, 1994; Pelicci et al., 1992) . After autophosphorylation of receptors, Shc is recruited to the receptor via phosphotyrosine binding motifs (Rozakis-Adcock et al., 1992; Egan et al., 1993) . The recent ®nding that the epidermal growth factor receptor (EGFR) requires the Shc SH2, while the insulin receptor (InsR) requires the Shc PTB to couple to mitogenesis (Ricketts et al., 1996) demonstrates that these domains may serve dierent functions. Shc binding to the receptor is followed by its phosphorylation on Y317, which forms a GRB2 binding site (Salcini et al., 1994) and results in recruitment of cytosolic GRB2/SOS complexes to the cell membrane (Rozakis-Adcock et al., 1992 , 1993 Chardin et al., 1993) . Once localized to the membrane, SOS-catalyzes the exchange of GDP for GTP on Ras (McCormick, 1993; Aronheim et al., 1994) .
The mechanism of Ras activation by G proteincoupled receptors has been far less clear. Recently, however, several G protein-coupled receptors have been shown to stimulate tyrosine phosphorylation of Shc Cazaubon et al., 1994; Sadoshima and Izumo, 1996; Chen et al., 1996) . In the case of G ilinked receptors, G bg subunits appear to mediate Shc phosphorylation, since expression of G bg subunits results in Shc phosphorylation Touhara et al., 1995) , and proteins that sequester G bg subunits block Shc phosphorylation by these receptors . G bg subunits from PTX sensitive G proteins stimulate Shc tyrosine phosphorylation through the cytosolic tyrosine kinase Src (Luttrell et al., 1996) . Less is known about the mechanisms by which receptors coupling to PTXinsensitive signaling events mediate Shc phosphorylation and Ras activation. While Src family proteins appear to be involved in this cascade (Schieer et al., 1996, Sadoshima and Izumo, 1996) , the G protein subunits involved in tyrosine kinase regulation have not yet been elucidated. In addition, a functional requirement for Shc in mitogenesis by G protein-coupled receptors has not yet been de®nitively demonstrated.
In 1321N1 astrocytoma cells thrombin activates Ras and stimulates AP-1-dependent gene expression and mitogenesis through a PTX-insensitive, Ras-dependent mechanism (LaMorte et al., 1993; Post et al., 1996) . Thrombin-stimulated mitogenesis occurs through the PTX-insensitive G protein G 12 in these cells (Aragay et al., 1995) . Further, Ga 12 and thrombin activate similar signaling pathways. Expression of an activated form of Ga 12 increases Ras-GTP levels and AP-1 gene expression mediated by Ga 12 is Ras dependent (Aragay et al., 1995) . The observation that Ga 12 can signal to Ras pathways may explain its mechanism of transformation in ®broblasts (Xu et al., 1993; Chan et al., 1993; Jiang et al., 1993; VoynoYasenetskaya et al., 1994) ; however, the direct eectors of G 12 and mechanism by which Ga 12 activates Ras are unknown. In this study we have used multiple techniques to identify Shc, speci®cally the Shc SH2 domain, as a necessary mediator of mitogenic signaling by G 12 and the thrombin receptor.
Results

Thrombin stimulation results in tyrosine phosphorylation of Shc
To establish whether Shc might mediate thrombininduced proliferation, we ®rst determined whether thrombin stimulates tyrosine phosphorylation of Shc in 1321N1 cells. Lysates from thrombin-stimulated cells were immunoprecipitated with anti-Shc antibodies and analysed by immunoblotting with anti-phosphotyrosine antibodies. 1321N1 cells express at least three Shc isoforms (p46, p52 and p66). As shown in Figure 1 , 15 min of thrombin treatment stimulates a 3.2-fold increase in p52 Shc tyrosine phosphorylation. Thrombin increases p52 Shc tyrosine phosphorylation as early as one minute (data not shown). While others have observed increases in tyrosine phosphorylation of p46 and p66 Shc following stimulation of G protein coupled receptors or expression of G bg subunits (Cazaubon et al., 1994; Luttrell et al., 1996) , we do not detect changes in tyrosine phosphorylation of these isoforms following thrombin stimulation. The magnitude of Shc phosphorylation seen with thrombin was similar to that observed after treatment with fetal calf serum, the only mitogen which we have found to be as ecacious as thrombin in 1321N1 cells.
G 12 stimulates Shc phosphorylation
We previously demonstrated that G 12 transduces thrombin's mitogenic signals in 1321N1 cells and that expression of the GTPase-de®cient Ga 12 Q229L results in Ras activation (Aragay et al., 1995; Collins et al., 1996) . We hypothesized that Ga 12 may stimulate Ras through tyrosine kinase activation and Shc phosphorylation. To test this hypothesis, we asked whether Ga 12 expression could increase Shc tyrosine phosphorylation. Due to the low transfection eciency of 1321N1 cells these experiments were performed in Cos-7 cells. Cells were transfected with either control vector, wild type Ga12 (Ga 12 wt) or a constitutively active form of Ga 12 (Ga 12 Q229L). Two days after transfection the level of endogenous Shc phosphorylation was determined by immunoblotting as described in methods. As shown in Figure 2 , expression of either wt or activated Ga 12 increases p52 Shc tyrosine phosphorylation approximately twofold. This increase was comparable to that observed upon expression of G b1g2 in experiments published by others and carried out in our laboratory (data not shown). Since the activated mutant of Ga 12 is GTP-bound and should not bind G bg subunits, the eect of Ga 12 expression upon Shc phosphorylation is likely mediated by the a subunit. Thus, our ®ndings indicate that Ga 12 regulates the activity of a tyrosine kinase.
Thrombin-stimulated mitogenesis requires tyrosine phosphorylation and is Shc dependent
We next determined the role of tyrosine phosphorylation and Shc in thrombin-stimulated mitogenesis using microinjection.
Anti-phosphotyrosine antibodies (PY20), which block phosphotyrosine dependent protein-protein interactions by speci®cally binding to phosphorylated tyrosine residues, were microinjected into serum deprived 1321N1 cells. Control coverslips were injected with preimmune rabbit IgG. Next, cells were stimulated with thrombin or vehicle and processed for DNA synthesis as described in Materials and methods. While preimmune IgG has no eect, microinjection of anti-phosphotyrosine antibodies (PY20) p52 Shc Figure 1 Thrombin stimulates tyrosine phosphorylation of p52 Shc. 1321N1 cells were serum deprived for 48 h and stimulated with vehicle (BSA), 0.5 U/ml thrombin or 10% FCS for 15 min. Cells were processed for immunoblotting as described in Materials and methods. The upper panel shows the mean+SE of data from three to four independent experiments. The lower panel is an autoradiogram from one representative experiment. Tyrosine phosphorylation of immunoprecipitated p52 Shc was quantitated by scanning laser densitometry. The data are expressed as fold increase relative to BSA. (Figure 3 ). These data demonstrate a de®nitive requirement for tyrosine phosphorylation and Shc in thrombin-stimulated mitogenesis.
Thrombin-stimulated mitogenesis occurs through the SH2 and not the PTB of Shc
To elucidate the domains required for Shc function in thrombin signaling, we microinjected GST fusion proteins of Shc fragments containing either the Nterminal PTB (residues 1 ± 215, GST-Shc PTB), or the SH2 domain (residues 378 ± 471, GST-Shc SH2). Microinjection of GST-Shc PTB inhibits insulin stimulated mitogenesis in hlRcB cells (Ricketts et al., 1996) ; however, the same preparation of fusion protein does not decrease thrombin's mitogenicity in 1321N1 cells. As was observed with microinjection of both PY20 and anti-Shc antibodies, microinjection of GSTShc SH2 inhibits thrombin stimulated DNA synthesis by 85% (Figure 3) . Microinjection of the PLCg SH2 domain had no eect on mitogenesis, demonstrating that the inhibition mediated by the Shc SH2 was not a nonspeci®c eect of microinjecting SH2 domains or GST fusion proteins (Figure 3 ). Taken together, these results demonstrate a requirement for Shc function, mediated by the Shc SH2 domain, in thrombin-induced DNA synthesis.
The requirement for the Shc SH2 is early and transient
To determine the temporal nature of the requirement for Shc SH2 function in mitogenic signaling by thrombin, delayed microinjections were performed. In these experiments cells were microinjected following, rather than prior to, thrombin stimulation. Consistent with the time course of Shc tyrosine phosphorylation, injection of the Shc SH2 domain during the ®rst 10 min following thrombin treatment produces a complete inhibition of DNA synthesis (Figure 4) . Between 12 and 17 min after thrombin treatment (the longest time we could study due to thrombin-induced cell rounding), the Shc SH2 domain begins to lose its ability to block mitogenesis. These data demonstrate that the Shc SH2 performs an early, transient function in thrombin signaling.
G 12 signals through Shc, speci®cally the Shc SH2
Ga 12 and thrombin both activate AP-1-mediated gene expression through a pathway that requires Ras (Aragay et al., 1995; LaMorte et al., 1993) . To determine whether AP-1-dependent gene expression also depends upon the SH2 domain of Shc, 1321N1 cells were cotransfected with Ga 12 and either the SH2 domain of Shc or control vector. All cells were transfected with an AP-1 luciferase reporter gene. As shown in Figure 5 , coexpression of the SH2 domain of Shc inhibits Ga 12 mediated AP-1 gene expression by 75%. A similar depression of the Ga 12 response was observed with an epitope-tagged construct that also encodes the Shc SH2 domain. Expression of a Shc mutant with a phosphotyrosine binding-de®cient SH2 domain, Shc R401L, had no eect (data not shown). Thus, Ga 12 -mediated eects upon AP-1 gene expression, like those on DNA synthesis, are propagated through the Shc SH2 domain. 
Discussion
We have previously demonstrated that thrombin treatment induces Ras activation in 1321N1 cells and that the heterotrimeric G protein G 12 is required for thrombin-induced mitogenesis (LaMorte et al., 1993; Aragay et al., 1995) . While expression of an activated form of Ga 12 can activate Ras , the mechanism of Ras activation by this PTX-insensitive G protein is unclear, particularly as the direct eectors of Ga 12 are unknown. Several recent reports have implicated Shc in the activation of the Ras-MAP kinase pathway by receptors coupling to PTX-sensitive heterotrimeric G proteins (Cazaubon et al., 1994; van Biesen et al., 1995; Ptasnik et al., 1995) . In this report we present data suggesting that Shc also transduces thrombin and G 12 signals to gene expression and mitogenesis. Our results, in accordance with those of van Obberghen-Schilling's group (Chen et al., 1996) , indicate that Shc is phosphorylated in response to activation of the thrombin receptor. This ®nding alone does not indicate that Shc functions in a proliferative pathway. However, by microinjecting antibodies against phosphotyrosine or Shc, we have shown that tyrosine phosphorylation and Shc are indeed necessary for thrombin-stimulated mitogenesis in 1321N1 astrocytoma cells. These data extend those of a recent report demonstrating that a Shc mutant (Y317F), which acts as a dominant negative, inhibits thrombininduced focus formation in CCL39 cells (Chen et al., 1996) . However, it should be noted that in that study the transforming eect of thrombin was assessed in the presence of insulin, at concentrations sucient to activate the IGF-1 receptor which is expressed in ®broblasts and requires Shc for mitogenesis (Sasaoka et al., 1994) . Our data are thus the ®rst to demonstrate that thrombin transduces mitogenic signals through Shc in the absence of other growth factors.
The Shc antibody that we used is directed against the SH2 domain of the molecule. However, this antibody appears to inhibit function of other Shc domains. For example, microinjection of this antibody inhibits insulin-stimulated mitogenesis, which occurs through the PTB and not the SH2 domain of Shc (Ricketts et al., 1996) . We therefore investigated whether speci®c domain(s) were necessary for thrombin signaling. By microinjecting GST fusion proteins corresponding to dierent domains of Shc, we ®nd that the Shc SH2 domain mediates thrombin-stimulated BrdU incorporation while the Shc PTB domain does not.
The speci®c inhibition by the GST-Shc SH2 in thrombin stimulated astrocytoma cells is similar to that which we have recently seen with the EGFR in ®broblasts (Ricketts et al., 1996) . Delayed injection of the GST-Shc SH2 into thrombin stimulated astrocytoma cells results in a time course of inhibition similar to that observed with EGF-stimulated fibroblasts (Ricketts et al., 1996) . Ullrich's group recently reported that EGFR are activated in response to thrombin stimulation of Rat1 ®broblasts (Daub et al., 1996) . The mitogenic inhibition following microinjection of the GST-Shc SH2 in 1321N1 cells could therefore result from inhibition of an EGFR signaling component. However, we ®nd that EGF is a poor mitogen in 1321N1 cells, and more importantly, we ®nd that stimulation with thrombin does not result in tyrosine phosphorylation of the EGF receptor in this system (unpublished data). Thus, the thrombin receptor signals through another protein that also requires the SH2 domain of Shc for mitogenic signaling.
The inhibition of DNA synthesis following microinjection of the Shc SH2 domain could occur by several mechanisms. Basu et al. (1994) have observed that a tyrosine-phosphorylated peptide corresponding to the Shc SH2 binding site on the EGF receptor inhibits Shc tyrosine phosphorylation in permeablilized cells, suggesting that the Shc SH2 may function upstream of Shc tyrosine phosphorylation. In this scenario, injection of the Shc SH2 would prevent tyrosine phosphorylation of Shc following thrombin receptor stimulation and thus impede formation of Shc-Grb2-SOS complexes. Alternatively, microinjection of the Shc SH2 domain may disrupt the function of tyrosine phosphatases which can act as positive mediators of thrombin-stimulated mitogenesis (Rivard et al., 1995) . By binding to phosphotyrosine residues, the Shc SH2 domain could block access of tyrosine phosphatases to their substrates and thereby prevent DNA synthesis.
Since the mitogenic eect of thrombin in 1321N1 cells is mediated by G 12 , we determined whether Shc was activated following G 12 expression. As seen with thrombin, Shc was tyrosine phosphorylated in response to expression of Ga 12 wt and Ga 12 Q229L. While it is unlikely that Shc is a direct eector of Ga 12 our data implicate Shc as an early mediator of G 12 signaling. To the best of our knowledge Shc is the most proximal G 12 eector described to date. Further our data suggest that Ga 12 , like G bg , can achieve its growth-promoting eects through the stimulation of a tyrosine kinase. The stimulation of tyrosine phosphorylation by Ga 12 suggests the hypothesis that G protein-coupled receptors that result in PTX-insensitive Shc phosphor- Figure 5 Ga 12 stimulates AP-1 gene expression through the Shc SH2. 1321N1 cells were transfected with the AP-1 dependent reporter gene 2XTRE-luciferase (2 mg/well) and the indicated plasmids (2 mg/well) as described in Materials and methods. Forty-eight hours later cells were lysed and luciferase activity was assayed. The data are expressed as the percent of stimulation by activated Ga 12 . The average stimulation by Ga 12 was 8.5-fold. Each bar represents the mean+SE of data from three to ®ve experiments performed in triplicate ylation may engage Shc through G 12 rather than G q . This hypothesis is supported by our earlier observation that expression of an activated form of Ga 12 results in increased Ras activation while expression of a similarly activated mutant Ga q does not .
Both thrombin and Ga 12 , but not G bg , elicit strong Ras-dependent stimulation of AP1 mediated gene expression in 1321N1 cells (LaMorte et al., 1993; Aragay et al., 1995) (unpublished observation). Our observation that Ga 12 -induced AP-1-dependent gene expression is inhibited by the Shc SH2 domain indicates that Shc, speci®cally the SH2 domain, is necessary for G 12 signaling. Thus in addition to causing tyrosine phosphorylation of Shc Ga 12 , like the thrombin receptor, utilizes Shc to propagate long term signals. Since Shc is an upstream mediator of Ras activation, our data suggest that Ras activation by Ga 12 and by the thrombin receptor (LaMorte et al., 1993) occur through the SH2 domain of Shc.
It is also important to note that while Ga 12 activates Ras, it stimulates the activity of the JNK but not the ERK family of MAP kinases Vara Prasad et al., 1995) . Thus, like many growth factors, Ga 12 can communicate to the JNK pathway through a Ras dependent mechanism (Minden et al., 1995; Vara Prasad et al., 1995; Collins et al., 1996) . Dominant negative proteins in the JNK pathway are eective inhibitors of AP-1 mediated gene expression by Ga 12 , while this response is insensitive to the MEK inhibitor PD090859 (our unpublished observations). From these observations it is tempting to speculate that G 12 achieves its mitogenic eects through the Ras dependent JNK family of MAP kinases and that Shc couples G 12 to this response.
Materials and methods
Cell culture and transfection
1321N1 cells were cultured in DMEM supplemented with 5% fetal calf serum and penicillin streptomycin at 37C in 10% CO 2 . Cells were plated at 3610 5 cells/well on 6 well plates the day prior to transfection by calcium phosphate coprecipitation with the indicated plasmids and the AP-1 dependent reporter gene 2XTRE luciferase as described (Trejo et al., 1992; Collins et al., 1996) . The next day, cells were washed and serum deprived. 48 hr later cells were harvested and assayed for either luciferase activity or Shc phosphorylation as described below. Cos-7 cells were cultured in DMEM supplemented with 10% fetal calf serum and penicillin streptomycin at 37C in 10% CO 2 . For transfection studies cells were set on 6 well plates at 2610 5 cells/well one day prior to transfection. Cells were transfected overnight using LipofectAMINE (Gibco) using a total of 2 mg total DNA and 4 ml lipofectAMINE per well. The following day cells were washed, serum deprived for 48 h and then processed for Shc phosphorylation as described.
Shc phosphorylation
1321N1 cells were plated on 6 well dishes as above and serum deprived for 48 h. Next cells were stimulated with either vehicle (0.1%BSA), 0.5 U/ml thrombin or 10% fetal calf serum for the indicated times and harvested in a lysis buer containing: 20 mM Tris pH 7.6, 150 mM NaCl, 3 mM EDTA, 3 mM EGTA, 20 mM b glycerophosphate, 0.5% vol/vol Nonidet P-40, 100 mM Na 3 VO 4 , 1 mM p-nitrophenylphosphate, 2 mM dithiothreitol, 1 mM phenylmethylsulphonyl¯oruoride, 10 mg/ml leupeptin and 10 mg/ml aprotinin. Shc was immunoprecipitated using anti-Shc antibodies (rabbit aShc, Transduction Labs), Immunoprecipitates were washed three times with lysis buer then boiled in Laemmli buer and resolved by 12% SDS ± PAGE. Proteins were transferred to Immobilon membranes which were then blocked with 3%BSA and probed with anti-phosphotyrosine antibodies (PY20, Transduction Labs). Cos-7 cells were washed after transfection and serum deprived for 48 h. Cells were harvested in the above lysis buer and endogenous Shc was immunoprecipitated (anti-Shc polyclonal, Transduction Labs), and analysed by immunoblotting as described for 1321N1 cells.
Plasmids pCis, pCisGa 12 wt and pCisGa 12 Q229L were the generous gifts of Dr Mel Simon (California Institute of Technology). The plasmid encoding the ShcSH2 in pcDNA3 was the generous gift of Dr John Shyy. HIS tagged ShcSH2 in pcDNA3.1/His C (Invitrogen) was generated as follows: residues 301 ± 504 were ampli®ed from murine Shc by PCR using primers containing a 5' BgIII site and a 3' EcoRI site. This fragment was then ligated into BamH1-and EcoR1-digested pcDNA3.1/His C. The plasmid encoding GST-Shc 1 ± 215 (ShcPTB) was the generous gift of Dr Steven Shoelson (Joslin Diabetes Center, Boston, MA). The plasmid encoding GST-Shc 378 ± 471 (ShcSH2) was the generous gift of Dr Alan Salteil (Parke Davis, Ann Arbor, MI). The GST-PLCg SH2 fusion protein was obtained from Santa Cruz (Santa Cruz, CA). Shc R401L (SH2 phosphotyrosine binding mutant) was the gift of Dr EY Skolnik.
Microinjection
GST fusion proteins were prepared and isolated from E. coli as recommended by Pharmacia. 1321N1 cells were plated onto glass coverslips at 40% con¯uency 2 days prior to injection. Cells were then serum deprived for 24 h, and microinjected with either fusion proteins or antibodies as described (Sasaoka et al., 1994) . In all conditions in which fusion proteins were microinjected, preimmune rabbit IgG was coinjected to enable detection of the injected cells. One hour after injection cells were stimulated with 0.5 U/ml thrombin (Calbiochem). Twelve hours later BrdU was added and cells were incubated for an additional 4 h. Coverslips were ®xed and stained as described (LaMorte et al., 1993; Aragay et al., 1995) and analysed using a Zeiss Axiophot¯uorescence microscope.
